Mirapexin eases restless legs

The licensed indications for the non-ergot dopamine agonist Mirapexin (pramipexole) have been extended to include the symptomatic relief of moderate to severe restless legs syndrome.

Restless legs syndrome, also known as Ekbom syndrome, is a neurological disorder characterised by an uncontrollable urge to move the legs that may be accompanied by painful sensations in the legs.

The condition worsens during the evening and some patients are so badly affected that it interrupts sleep and interferes with their daytime performance.

Starting at a dose of 0.125mg once daily taken two to three hours before bedtime, Mirapexin has been shown to provide relief from a broad range of symptoms of restless legs syndrome. In trials the onset of relief was rapid, occurring in as little as one week, and was accompanied by a marked improvement in the patient's quality of life. Should the patient fail to respond adequately, the dose may be increased every four to seven days up to a maximum of 0.75 mg once daily. The need for continued treatment should be evaluated after three months.

Further information: Boehringer Ingelheim Ltd, Ellesfield Avenue, Bracknell, Berkshire RG12 8YS. Tel: (01344) 424600.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more